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Abstract 
 
Background: In pre-clinical animal studies the uniformity of dosing across subjects 
and routes of administration is a crucial requirement. In preparation for a study in 
which aerosolized live-attenuated measles virus vaccine was administered to 
cynomolgus monkeys (Macaca fascicularis) by inhalation, we assessed the 
percentage of a nebulized dose inhaled under varying conditions.  
Methods: Drug delivery varies with breathing parameters therefore we determined 
macaque breathing patterns (tidal volume, breathing frequency and inspiratory to 
expiratory (I:E) ratio) across a range of 3.3 - 6.5 kg body weight, using a pediatric 
pneumotachometer interfaced either with an endotracheal tube or a facemask. 
Subsequently, these breathing patterns were reproduced using a breathing simulator 
attached to a filter to collect the inhaled dose. Albuterol was nebulized using a 
vibrating mesh nebulizer and the percentage inhaled dose was determined by 
extraction of drug from the filter and subsequent quantification.  
Results: Tidal volumes ranged from 24 to 46 ml, breathing frequencies from 19 to 31 
breaths per minute and I:E ratios from 0.7 to 1.6. A small pediatric resuscitation mask 
was identified as the best fitting interface between animal and pneumotachometer. 
The average efficiency of inhaled dose delivery was 32.1% (standard deviation 7.5, 
range 24-48%), with variation in tidal volumes as the most important determinant.  
Conclusions: Studies in non-human primates aimed at comparing aerosol delivery 
with other routes of administration should take both the inter-subject variation and 
relatively low efficiency of delivery to these low body weight mammals into account. 
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Introduction 
 
Aerosol inhalation is used routinely in respiratory medicine for pulmonary drug 
delivery.(1) The most common application is treatment of chronic pulmonary diseases 
such as asthma and cystic fibrosis.(2, 3) In recent years aerosol inhalation has also 
been considered as an alternative route of vaccine delivery.(4-6) Vaccination is mostly 
performed in children, and this presents particular challenges for efficient pulmonary 
delivery and dose control.(7, 8) This is especially true in very young infants who have 
low tidal volumes(9) and variable breathing patterns.(10) In addition, small children 
often do not tolerate aerosol masks, and agitation may cause air leakage at the 
edges of the facemask.(11-13) As a result, the efficiency of lung deposition in infants 
may fall below 1%.(14, 15)  
New drugs and biologicals for which human efficacy studies are not ethical or 
feasible may be evaluated according to the “animal rule”, which requires well-
characterized animal models .(16) In some cases such studies need to be performed 
in non-human primates. Aerosol delivery to non-human primates meets with similar 
challenges as those seen for aerosol delivery to infants.(14, 17) Macaques have low 
body weights and hence low tidal volumes, they are obligate nose breathers, and are 
not cooperative. In many preclinical animal studies this has been solved in part by 
using exposure chambers that fit the complete head of the animal.(18, 19) However, 
this method has practical limitations for the administration of vaccines, where direct 
administration to the airways is preferable. We have previously used a nebulizer in 
combination with a facemask to deliver measles virus (MV) vaccine(20) or wild-type 
MV (21, 22) to sedated cynomolgus macaques (Macaca fascicularis). Although these 
studies were successful, they allowed limited control over the actual inhaled dose, 
amongst others because the facemask used was not tight fitting. In preparation for a 
measles vaccination study in macaques designed to compare different routes of 
vaccine administration, we set out to optimize aerosol delivery options and quantify 
inhaled doses of macaques. In this study, we describe a series of experiments 
performed to obtain basic information on respiration characteristics of sedated 
cynomolgus macaques, to identify an optimally-fitting facemask, and to perform 
dose-normalization studies. 
 
Materials and Methods 
 
Ethics statement 
The animal studies were performed in subadult male cynomolgus monkeys 
(Table 1). Animal experiments were conducted in compliance with European 
guidelines (EU directive on animal testing 86/609/EEC) and Dutch legislation 
(Experiments on Animals Act, 1997). The protocol (nr. EMC2373) was approved by 
the independent animal experimentation ethical review committee DCC in 
Driebergen, The Netherlands. This committee is not affiliated to the Erasmus MC, 
where the experiments were performed. Animals were housed in groups, received 
standard primate feed and fresh fruit on a daily basis and had access to water ad 
libitum. In addition, their cages contained multiple sources of environmental 
enrichment in the shape of hiding places, hanging ropes, tires and other toys. Animal 
welfare was observed on daily basis, and animal handling and tidal breathing 
measurements were performed under light anesthesia using a cocktail of ketamine 
and medetomidine (intramuscular dose of 10 and 0.04 mg/kg bodyweight, 
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respectively). After handling, atipamezole was administered to antagonize the effect 
of medetomidine. No animals were sacrificed during this study. 
 
Measurement of macaque breathing patterns 
A pediatric pneumotachometer (MasterScreen Paed, Jaeger, CareFusion) in 
combination with JLAB 4.67 software was used to measure tidal volume (Vt), breaths 
per minute (BPM) and ratio of inspiratory to expiratory time (I:E ratio). Measurements 
consisted of duplicate or triplicate assessment of runs of approximately 20 breaths 
for each animal. The five lowest and highest values were automatically discarded to 
provide average values for the median ten measurements. Initially tidal breathing 
measurements were performed after intubation with a 3.5 mm or 5 mm endotracheal 
tube, subsequent measurements were performed using facemasks. 
 
Selection of macaque facemasks 
Several pediatric facemasks of different sizes and brands were evaluated for 
their potential fit on the faces of macaques. These masks were evaluated by 
comparing breathing parameters measured using the pneumotachometer through the 
endotracheal tube with those obtained through the facemask. The majority of 
facemasks resulted in considerable air leakage, resulting in invalid tidal breathing 
measurements. Based on this preliminary screening, two pediatric resuscitation 
masks were selected for further testing: LSR Silicone no. 0/1 (Laerdal 851600) and 
no. 0/0 (Laerdal 851500). Similar masks had been previously identified as highly 
efficient in achieving a tight seal in infants.(11)  
 
Breathing simulation: aerosol efficiency and mass balance measurement 
A breathing simulator (ASL5000, Ingmar Medical), programmed to simulate 
the recorded macaque breathing patterns, was attached to an absolute filter 
(Respirgard 303, Baxter). To determine delivered dose, a nebulizer (Aerogen Pro, 
Aerogen Ireland Ltd., mass median aerodynamic diameter 3.5 µm) with adapter (22 
mm T-piece, Aerogen) was attached to the collecting filter (Figure 2E). A nominal 
dose of 0.5 ml (2.5 mg) albuterol sulphate (Ventolin, 5 mg/ml, Allen & Hansbury) was 
nebulized in each test run. Albuterol was eluted from filter or nebulizer components 
using a 1:4 mix of 96% (v/v) HPLC-grade ethanol in water. Albuterol mass, 
expressed as a fraction of the nominal dose, was determined using UV 
spectrophotometry (Biochrom UV Vis, Cambridge, UK) and interpolation on a 
standard curve at 276 nm. Albuterol was used as it is a commonly nebulized 
formulation used in the characterization of aerosol drug delivery systems, and is 
specified for use as a tracer aerosol in the international standard.(23) Previous 
comparison of nebulization of albuterol or measles vaccine using a similar vibrating 
mesh nebulizer had shown no differences in output rate or VMD.(24) Mass balances 
were also recorded for all four configurations. Mass balance characterization of 
configuration D with the breathing simulator is shown in Figure 2E. All dosing times 
were recorded. All test iterations were run in triplicate.  
 
Results 
 
Macaque breathing patterns 
Plethysmography was used to record the breathing parameters in subadult 
cynomolgus macaques. Sixteen valid measurements were obtained (Table 1): three 
by endotracheal intubation (A), four by using the larger facemask (B) and nine by 
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using the smaller facemask (C). Of the facemasks tested, the large resuscitation 
mask (Laerdal 0/1) showed significant air leakage in the majority of animals tested 
(Figure 1A), resulting in invalid measurements that were excluded from subsequent 
analysis. The small resuscitation mask (Laerdal 0/0) showed the best fit to the face of 
macaques. As macaques are obligate nose breathers, the best way to fit the mask 
proved to be placing the mask on the face of the animal, and subsequently move it to 
a slightly upward position (Figure 1B). Measurements obtained from a representative 
individual animal are shown as examples (Figure 1C and D). Data obtained with the 
smaller facemask were used for all further bench testing. 
 
Dose delivery 
A breathing simulator was used to characterize the dose efficiency of four 
nebulizer configurations (Figure 2 A-D). The first configuration (Figure 2A) was 
previously used for experimental MV infections of macaques.(21, 22) In a second 
configuration, the small connector between T-piece and breathing simulator was 
removed to prevent obstruction of airflow and reduce impactional aerosol losses 
exiting the nebulizer (Figure 2B). Subsequently, configurations C and D were 
prepared by using a neonate T-piece (C, diameter 12 mm) or an adult T-piece (D, 
diameter 22 mm) extended with a straight 22 mm tube. To compare the four 
configurations, the delivery efficiency was determined by measuring the percentage 
inhaled dose of albuterol sulphate as a tracer compound, using the average values 
obtained using the small resuscitation mask (Table 1, C-AVG) to program the 
breathing simulator.  
The best performing configurations were D and B. The difference in respective 
inhaled doses for configurations D and B were not statistically significant (p=0.443), 
however, on the basis that configuration D did deliver a higher inhaled dose, with a 
low standard deviation between runs, it was decided to proceed with configuration D. 
Furthermore, configuration D delivered a significantly higher inhaled dose than both 
configuration A (p<0.004) and configuration C (p<0.001) (Table 2, see values shown 
in column ‘Inhalation filter’). The mean time to delivery of the 0.5 ml dose was 75 ± 1 
seconds (approximately 0.4 ml of albuterol sulphate/min) across all tests carried out.  
 
Mass balance measurements 
The results showed that for all configurations more than half the dose 
remained in the T-piece as condensate (Table 2 and Figure 2F). The highest levels 
of condensate in the T-piece were recorded in configurations A and C. The remaining 
fractions were detected in the inhalation filter, exhalation filter and nebulizer as 
residual mass. The standard deviations recorded for the test iterations were low, 
indicating good reproducibility of dosing between replicate measurements.  
 
Influence of tidal volume (Vt), respiratory rate and I:E ratio on inhaled dose 
efficiency 
At average Vt values, the influence of maximal or minimal respiratory rate 
(BPM) and/or I:E ratios (Table 1) on dose efficiency was relatively limited (Table 3). 
However, at average BPM or I:E, the Vt had a major effect on inhaled dose efficiency. 
These results are in agreement with the convention that larger animals will usually 
inhale a greater dose. Interestingly, with average BPM this was especially notable in 
combination with low I:E ratios (Table 3). A Pearson correlation coefficient analysis of 
all combinations of breathing parameters was carried out. Following this analysis, the 
only significant relationship identified was between Vt and dose efficiency (p = 0.002). 
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The Pearson correlation coefficient was 0.786, confirming that a strong direct 
relationship exists between the two.  
Further, a regression analysis was conducted in an attempt to identify a 
mathematical prediction model for dose efficiency. The resulting equation was as 
follows: [Dose efficiency = 6.28 + 0.537 Vt + 0.290 BPM - 4.15 I:E], with a R2 of 
72.2 %. As expected from the previous analysis, the most significant variable 
impacting dose efficiency was confirmed to be Vt (p=0.003). Whilst a R2 of 72.2 % is 
relatively strong, it can predict only 72.2 % of the variability in this system. Means of 
improving this correlation include increasing animal numbers, increasing 
measurement sensitivity and other variations in the experimental setup. 
 
Discussion 
 
The goals of this study were to obtain baseline data for breathing 
characteristics of sedated cynomolgus macaques, determine the best fitting 
facemask as optimal interface between animal and nebulizer and assess the 
efficiency of inhaled dose delivery over a range of representative macaque breathing 
parameters. To achieve these goals, a pediatric pneumotachometer was used for 
tidal breathing measurements in animals of different body weights, and the obtained 
values were used to program a pediatric breathing simulator and assess delivery 
efficiency using a commonly used “tracer” aerosol. 
The tidal breathing measurements in macaques were not designed to 
compare baseline data obtained through endotracheal tube or resuscitation mask. 
Instead, they were intended to select the best fitting facemask in preparation of a 
subsequent vaccination study, and use this mask to collect baseline data for bench 
testing of dose delivery. This resulted in the unbalanced datasets presented in table 
1. After three successful measurements of baseline characteristics through an 
endotracheal tube (dataset A) we saw no reason (and hence considered it unethical) 
to repeat these measurements in more animals. After several unsuccessful 
measurements with the large resuscitation mask (dataset B in table 1 only includes 
the measurements that resulted in valid data) we again considered it unethical to 
continue measurements in more animals. It was only with the small resuscitation 
mask (dataset C) that we were able to be able to reproducibly collect useful data 
from several different animals. The datasets for A and B are presented for 
information only in Table 1. By tilting the facemask upwards (Figure 1B), we were 
able to allow normal breathing with minimal air leakage. Breathing parameters 
showed substantial variation between animals (Table 1), of which some could be 
explained by differences in body weight (tidal volumes) while others seemed to be 
related to either individual differences or depth of anesthesia. Of note regarding the 
relevance of this study, the average tidal volume of 7 ml per kg body weight (Table 1) 
is almost identical to that of children.(25, 26) All tidal volume measurements were 
performed under anesthesia using ketamine and medetomidine, both agents known 
to potentially suppress respiration.(27, 28) However, in our experience animals this 
sedation protocol results in reproducible and stable breathing. Interestingly, tidal 
volume and respiratory rate data obtained were close to those previously reported for 
conscious cynomolgus macaques (26 ml and 30 BPM, respectively).(29) 
With standard continuous jet nebulizers, inhaled dose is less associated with 
change in Vt or BPM than I:E ratio.(30) However, with the vibrating mesh nebulizer 
used on our study, I:E ratio was found to be less of a factor than Vt. This may be a 
result of the lack of continuous flow generated with jet nebulizers and the bolus 
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inhalation facilitated by the T-piece used in conjunction with the vibrating mesh 
nebulizer. The generation of a bolus using jet nebulizers is not possible in this setup 
given that the driving gas will act to continually clear the T-piece. 
The efficiency of dose delivery between four different nebulizer configurations 
was compared using the average Vt, I:E ratio and breathing frequency recorded for 
macaques. In all cases more than half the dose was deposited as condensate in the 
T-piece (Table 2). Configuration D showed the highest delivery efficiency, as 
determined by the highest percentage of the albuterol detected on the filter. We 
assume that the gains in efficiency in this configuration was due to the larger internal 
volume of the assembly, acting as a reservoir from which a larger bolus of aerosol 
could be inhaled with each breath. The internal volumes for each of Configurations A 
– D were 55.0, 59.5, 32.0 and 56.5 ml, respectively. Nevertheless, only 24-48 % of 
the nebulized dose was actually delivered to the inhalation filter, representing that 
dose available to the face of macaques. These values are in the same order of 
magnitude as the deposition efficiencies previously reported in cynomolgus 
macaques.17 Of particular note, the waste residual dose left un-nebulized within the 
nebulizer was consistently low across all configurations (range 2.1 to 3.2 % of the 
nominal dose). In the selection of devices for delivery of high value therapeutics, this 
is an important point of comparison against alternate aerosol generator technologies 
with higher residual volumes, e.g. jet nebulizers.  
Based on the tidal breathing measurements obtained, the impact of Vt, BPM 
and I:E ratios on dose efficiency was assessed. Using the average value for one 
parameter, the effect of minimal and maximal values of the other two was evaluated. 
Overall, Vt was seen to have the greatest effect on delivery. However, it should be 
noted that the maximum Vt (46 ml) was recorded in an animal with a body weight of 
6.5 kg. Varying both BPM and I:E ratio whilst maintaining Vt at the “average” value, 
was not associated with significant effects on dose efficiency (range 22.48 to 26.71 
%). However, all other combinations of Vt, BPM and I:E were seen to result in much 
wider ranges of delivery efficiencies (Average BPM, range 20.42 to 39.70 %, 
Average I:E, range 21.30 to 38.70 %). We conclude that when using a vibrating mesh 
aerosol generator with connecting circuit that acts as a reservoir, and a properly 
fitting mask, we found less difference between delivery efficiency than anticipated, 
and recommend that in an aerosol-mediated delivery study in non-human primates 
standardized body weights should be used to ensure comparable dosing.  
This study has some limitations. Practical and ethical limitations to working 
with non-human primates mean we were unable to obtain a larger number of tidal 
breathing measurements. However, the data provide a solid level of internal 
consistency. Although all subjects received moderate sedation, it is possible that 
animals responded differently. However, this same type of response is commonly 
observed in non-anesthetized infants during administration of aerosols via a 
facemask. Another limitation of our study is that we cannot distinguish between 
delivery to the upper or lower respiratory tract, and provide data on inhaled dose 
only. In anatomically correct infant airway models such as the SAINT,(31) it has been 
demonstrated that the inhaled dose found at the mouth does not have a linear 
correlation with the dose to the lungs. Therefore, the estimated efficiency of 24-48 % 
is only valid for inhaled delivery of the aerosol to the respiratory tract, with a fraction 
of this dose expected to be delivered to the lungs. Finally, use of albuterol solution as 
a tracer aerosol may not fully predict the aerosol performance of alternative 
formulations.  
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In conclusion, studies in non-human primates aimed at comparison of aerosol 
vaccination with other routes of vaccine delivery must take both the inter-subject 
variation and relatively low efficiency of delivery to these low body weight mammals 
into account. Especially important in the case of vaccines where a fixed dose is 
administered irrespective of body weight. Specifically, selection of body weight-
matched subjects and an appropriate aerosol delivery system shall serve to 
effectively control inter and intra dose variation.  
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Table 1: Tidal breathing and inhaled doses. Tidal volume measurements were 
performed by plethysmography in ten subadult male cynomolgus macaques, using 
either endotracheal intubation (A), Laerdal facemask 0/1 (B) or Laerdal facemask 0/0 
(C) as interface.  
 
Interface Animal 
ID # 
Age 
(months) 
BW
(kg) 
Vt1 (ml) BPM2 I:E 
ratio3 
Calculated 
ml / kg 
% Inhaled dose
average (SD) 
A* 1 56 4.1 25.6 32.0 0.52 6.24 NT 
A** 1 56 4.1 26.4 28.2 0.78 6.44 NT 
A** 2 57 5.7 32.9 36.0 0.98 5.77 NT 
B 2 57 5.7 34.4 17.8 1.36 6.04 NT 
B 3 55 4.3 24.4 27.7 0.72 5.67 NT 
B 3 55 4.3 27.3 26.2 0.84 6.35 NT 
B 4 55 3.5 25.0 22.3 0.72 7.14 NT 
C 1 56 4.1 26.9 20.7 0.80 6.56 26.67 (0.73) 
C 3 55 4.3 27.8 25.7 0.68 6.47 31.62 (1.15) 
C 4 55 3.5 28.5 19.4 0.73 8.14 26.48 (0.58) 
C 5 56 3.7 25.2 20.0 1.30 6.81 24.05 (0.92) 
C 6 57 6.5 27.4 28.4 1.15 4.22 29.10 (1.66) 
C 6 57 6.5 24.0 29.6 1.39 3.69 26.48 (0.97) 
C 7 54 6.5 46.0 28.7 0.86 7.08 48.05 (0.68) 
C 8 55 4.1 35.4 27.9 1.32 8.63 37.48 (1.05) 
C 9 55 3.3 24.2 31.1 1.61 7.33 30.19 (0.93) 
C-Min4 -- -- -- 24.0 19.4 0.68 3.69 24.05 
C-Max5 -- -- -- 46.0 31.1 1.61 8.63 48.05 
C-AVG6 -- -- -- 29.5 25.7 1.09 6.51 32.12 
C-STD7 -- -- -- 7.1 4.5 0.33 1.64 7.46 
1 Vt = tidal volume; 2BPM = breaths per minute; 3 I:E ratio = ratio of length of 
inspiration over expiration time; 4minimal, 5maximal and 6average (7standard 
deviation) values measured for Vt, BPM and I:E using the small resuscitation mask 
(C); * = endotracheal tube 3.5 mm; ** = endotracheal tube 5 mm. NT: not tested.
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Table 2: Mass distributions of albuterol sulphate after nebulization using different 
configurations (as shown in Figure 1 A-D). The configurations were connected to a 
breathing simulator (Figure 1E), which was programmed using the C-AVG values for 
tidal volume, I:E ratio and respiration rate (Table 1). Results are shown as 
percentages of nominal dose placed in the nebulizer that were recovered from each 
compartment, represented as means ± standard deviation of triplicate 
measurements. The percentage found in the inhalation filter represents the delivery 
efficiency. 
 
Config Inhalation filter Exhalation filter Nebulizer T-Piece Sum
A 20.48 ± 0.22 17.33 ± 3.82 3.24 ± 3.24 58.26 ± 1.59 99.31 
B 24.95 ± 4.00 15.10 ± 0.73 2.81 ± 0.37 50.62 ± 0.72 93.48 
C 22.14 ± 0.86 14.67 ± 0.54 2.05 ± 0.25 59.95 ± 0.75 98.81 
D 26.71 ± 0.80 17.71 ± 0.80 2.21 ± 0.38 52.29 ± 0.61 98.92 
 
 
 
Table 3: Delivery efficiency of configuration D across combinations of C-min, C-max 
and C-AVG values of Tidal Volume, I:E ratio and BPM. 
 
 Average STDEV MIN MAX 
Average Vt  
min BPM min I:E 22.48 1.06 
22.48 26.71 
max BPM max I:E 26.71 0.37 
max BPM max I:E 23.52 2.38 
max BPM min I:E 26.43 1.19 
Average BPM     
min Vt min I:E 21.87 1.81 
20.42 39.70 
max Vt max I:E 23.12 1.40 
min Vt max I:E 20.42 1.40 
max Vt min I:E 39.70 1.69 
Average I:E     
min Vt min BPM 21.30 1.21 
21.30 38.70 
max Vt max BPM 38.70 1.45 
min Vt max BPM 23.89 2.34 
max Vt max BPM 33.89 1.47 
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Figure 1: Tidal breathing measurements. Tidal volumes, BPM and I:E ratios were 
measured using a pediatric pneumotachometer, either by endotracheal intubation 
(not shown), large resuscitation facemask (A,) or a small resuscitation facemask (B). 
Patterns for inspiratory and expiratory flows and volumes for one of the 
measurements of (C, animal #1). Triplicate measurements of the same animal (D). 
 
 
  
12 
 
Figure 2: Breathing simulator measurements. Four different nebulizer 
configurations (A-D) were used to test the dose efficiency. Configuration D was used 
with a filter on the expiratory side for mass balance measurements (E). Significant 
losses were observed as rainout of the aerosol in the t-piece (F). NOTE: 
Configurations A and B differ only in the use of a 22 mm outer diameter connector 
between the T-piece and Filter for Configuration A. Configuration B incorporates a 
22 mm inner diameter connector between the T-piece and Filter. 
 
 
 
